Nascent Biotech, Inc. Stock Other OTC
Equities
NBIO
US63108Q1013
Biotechnology & Medical Research
Financials (USD)
Sales 2022 | 1 | Sales 2023 | - | Capitalization | 7.16M |
---|---|---|---|---|---|
Net income 2022 | - | Net income 2023 | -2M | EV / Sales 2022 | 6,213,671 x |
Net cash position 2022 | 94.41K | Net Debt 2023 | 217K | EV / Sales 2023 | - |
P/E ratio 2022 |
-13.1
x | P/E ratio 2023 |
-2.38
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 60% |
Managers | Title | Age | Since |
---|---|---|---|
Sean Carrick
CEO | Chief Executive Officer | 56 | 14-07-14 |
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14-07-14 |
Douglas Karas
BRD | Director/Board Member | 59 | 16-04-03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lowell Holden
DFI | Director of Finance/CFO | 82 | 14-07-14 |
Sean Carrick
CEO | Chief Executive Officer | 56 | 14-07-14 |
Douglas Karas
BRD | Director/Board Member | 59 | 16-04-03 |
1st Jan change | Capi. | |
---|---|---|
+8.93% | 105B | |
-0.53% | 104B | |
+5.79% | 22.94B | |
-12.75% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-8.82% | 16.96B | |
+8.06% | 14.16B | |
+39.43% | 12.63B |